Published in Ann N Y Acad Sci on August 12, 1993
Intratumoral immunotherapy: using the tumour against itself. Immunology (2005) 0.97
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90
Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. J Immunol Res (2014) 0.81
The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature (1991) 5.40
Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol (1978) 2.81
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther (1999) 2.00
Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res (1975) 1.75
Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res (1999) 1.58
Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol Immunother (1996) 1.44
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res (1988) 1.32
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol (1986) 1.30
Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol (1967) 1.30
Bacillus Calmette-Guerin in the treatment of neoplastic disease. J Reticuloendothel Soc (1974) 1.29
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res (1986) 1.25
Protracted survival after resection of metastatic uveal melanoma. Cancer (2000) 1.21
Laparoscopic splenectomy: outcomes and lessons learned from over 200 cases. Surgery (2000) 1.20
Hepatitis A virus infection among homosexual men. BMJ (1991) 1.18
Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res (1984) 1.14
Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer (1992) 1.14
Interleukin 10 production by human melanoma. Clin Cancer Res (1996) 1.12
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother (1998) 1.09
A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission. Cancer (1976) 1.06
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer (1975) 1.05
Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene (1989) 1.02
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res (1994) 1.01
Cyclophosphamide intensifies the acquisition of allergic contact dermatitis in mice rendered B-cell deficient by heterologous anti-IgM antisera. Immunology (1979) 1.01
Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol (1990) 1.01
Augmentation of the human immune response by cyclophosphamide. Cancer Res (1982) 1.00
Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res (1987) 1.00
Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. Int J Cancer (1975) 0.99
BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res (1997) 0.99
Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest (1988) 0.98
Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest (1997) 0.97
Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol (1990) 0.97
STD and HIV screening in general practice: a survey related to termination of pregnancy in south Thames. Br J Gen Pract (1998) 0.97
Theory and application of early systemic therapy. Semin Oncol (1991) 0.96
Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol (1999) 0.96
Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol (1997) 0.96
Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology (1991) 0.96
Current concepts of the biology of human cutaneous malignant melanoma. Adv Cancer Res (1977) 0.95
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep (1987) 0.95
In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol (1996) 0.95
Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer (2001) 0.94
Systemic chemotherapy for metastatic melanoma. Semin Oncol (1988) 0.94
Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype. J Interferon Cytokine Res (1998) 0.94
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer (1989) 0.93
Evaluating minimally invasive surgery training using low-cost mechanical simulations. Surg Endosc (2003) 0.93
Experimental photoallergic contact dermatitis: a mouse model. J Invest Dermatol (1982) 0.93
Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res (1984) 0.92
Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer (1976) 0.92
Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother (1994) 0.91
Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother (1995) 0.91
Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer (2000) 0.91
Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res (1991) 0.91
Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol (2001) 0.90
Endoscopic retrograde cholangiopancreatography in the management of choledocholithiasis. Surg Endosc (2000) 0.89
Obesity and laparoscopic repair of ventral hernias. Surg Endosc (2001) 0.89
Immunologic approaches to the treatment of prostate cancer. Semin Oncol (1999) 0.89
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol (2000) 0.88
Phase I study of 5-azacytidine (NSC-102816) . Cancer Chemother Rep (1972) 0.88
Effect of the H37Ra strain of M. tuberculosis and of a mycobacterial RNA fraction on tumor growth. Proc Soc Exp Biol Med (1974) 0.87
Precursor lesions in familial melanoma. Semin Oncol (1978) 0.86
A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer (1973) 0.86
Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents. J Natl Cancer Inst (1979) 0.86
Laparoscopic dissecting instruments. Semin Laparosc Surg (2001) 0.86
Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol (1998) 0.85
Proceedings: Further studies on sensitization to picric acid. Monogr Allergy (1974) 0.84
Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr (1973) 0.83
Specific acquired immune unresponsiveness to contact allergens with cyclophosphamide in the mouse. Int Arch Allergy Appl Immunol (1976) 0.83
Relapse of infant botulism. Ann Neurol (1990) 0.83
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer (1975) 0.83
Exaggerated delayed-type hypersensitivity to simple chemical allergens in the guinea pig. J Invest Dermatol (1967) 0.83
Diffuse primary malignant melanoma after prior primary cutaneous malignant melanoma. Arch Ophthalmol (1980) 0.83
Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep (1976) 0.83
Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol (1985) 0.82
Other cancers in uveal melanoma patients and their families. Am J Ophthalmol (1989) 0.82
Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol (1998) 0.82
Diagnosis and management of diseases affecting the motor unit in infancy. R I Med J (1989) 0.82
Serotherapy of cancer. Semin Oncol (1989) 0.82
Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). Cancer Chemother Rep (1974) 0.82
The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol (1986) 0.81
Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep (1976) 0.81
Metastatic melanoma of the maxilla presenting as a gingival swelling. Oral Surg Oral Med Oral Pathol (1976) 0.81
Cutaneous melanoma in a patient with neurofibromatosis. Arch Dermatol (1979) 0.81
Regulation of contact allergy in the B cell--deficient mouse. Ann N Y Acad Sci (1982) 0.81
Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum. J Immunol (1989) 0.81
Combination chemotherapy of metastatic melanoma. J Clin Oncol (1995) 0.80
Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma. Cancer Chemother Rep (1976) 0.80
Systemic therapy in melanoma. Semin Surg Oncol (1998) 0.80
Determinants of competency judgments by experienced laparoscopic surgeons. Surg Endosc (2003) 0.80